Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer

ConclusionTumors responding to first-line chemotherapy also responded better to subsequent lines, whereas PDfl mCRCs remained refractory, which may explain the better survival associated with ETSfl.Key Points• Early shrinking tumors under first-line chemotherapy responded better to subsequent lines, maintaining low tumor loads, potentially explaining the link between early tumor shrinkage and overall survival of metastatic colorectal cancer (mCRC) patients.• mCRCs progressing under first-line chemotherapy remained refractory to other therapies and their tumor loads increased rapidly.• Even outside a clinical trial, an early first CT scan reevaluation with RECIST criteria 8 weeks after starting first-line therapy is crucial to determine long-term mCRC evolution.
Source: European Radiology - Category: Radiology Source Type: research